{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:46:41Z","timestamp":1790833601692,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP631632"],"award-info":[{"award-number":["APP631632"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1026922"],"award-info":[{"award-number":["APP1026922"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1063214"],"award-info":[{"award-number":["APP1063214"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1059354"],"award-info":[{"award-number":["APP1059354"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["094977\/Z\/10\/Z"],"award-info":[{"award-number":["094977\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","award":["CIEF grant 2011001686"],"award-info":[{"award-number":["CIEF grant 2011001686"]}],"id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003550","name":"Queensland Government","doi-asserted-by":"publisher","award":["Smart Futures PhD scholarship"],"award-info":[{"award-number":["Smart Futures PhD scholarship"]}],"id":[{"id":"10.13039\/501100003550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002293","name":"Department of Industry and Science, Australian Government","doi-asserted-by":"publisher","award":["Australian Postgraduate Award"],"award-info":[{"award-number":["Australian Postgraduate Award"]}],"id":[{"id":"10.13039\/501100002293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2018.01420","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T04:20:02Z","timestamp":1530505202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay"],"prefix":"10.3389","volume":"9","author":[{"given":"Angie M.","family":"Jarrad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A. T.","family":"Blaskovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anggia","family":"Prasetyoputri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Karoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl A.","family":"Hansford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5694\/j.1326-5377.1970.tb49948.x","article-title":"An optimal zone of colistin activity with Serratia marcescens.","volume":"2","author":"Annear","year":"1970","journal-title":"Med. J. Aust."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits spore production in Clostridium difficile.","author":"Babakhani","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.","volume":"60","author":"Babakhani","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1128\/AAC.00760-10","article-title":"Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant Enterococci to effect rapid bacterial killing.","volume":"54","author":"Belley","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/gut.27.10.1169","article-title":"Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.","volume":"27","author":"Bolton","year":"1986","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: back to the future.","volume":"67","author":"Butler","year":"2014","journal-title":"J. Antibiot."},{"key":"B7","year":"2013","journal-title":"Antibiotic Resistance Threats in the United States, 2013."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1128\/AAC.00061-14","article-title":"Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus.","volume":"58","author":"Cheng","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1039\/C3OB42428F","article-title":"Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.","volume":"12","author":"Cheng","year":"","journal-title":"Org. Biomol. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/jac\/dkv006","article-title":"In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.","volume":"70","author":"Corbett","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.","volume":"55","author":"Crook","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1093\/jac\/dkx299","article-title":"Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.","volume":"72","author":"Daley","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.107.2767.44","article-title":"A paradoxical zone phenomenon in the bactericidal action of penicillin in vitro.","volume":"107","author":"Eagle","year":"1948","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10096-007-0411-4","article-title":"Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.","volume":"27","author":"Fleischhacker","year":"2007","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.anaerobe.2009.12.002","article-title":"Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.","volume":"16","author":"Goldstein","year":"2010","journal-title":"Anaerobe"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1086\/430350","article-title":"Eagle effect in Corynebacterium diphtheriae.","volume":"191","author":"Grandi\u00e8re-P\u00e9rez","year":"2005","journal-title":"J. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1128\/AAC.34.1.94","article-title":"Paradoxical activity of beta-lactam antibiotics against Proteus vulgaris in experimental infection in mice.","volume":"34","author":"Ikeda","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40506-015-0062-4","article-title":"Clostridium difficile infection: current and emerging therapeutics.","volume":"7","author":"Jarrad","year":"2015","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejmech.2016.04.064","article-title":"Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.","volume":"120","author":"Jarrad","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1128\/AAC.36.10.2342","article-title":"Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.","volume":"36","author":"Johnson","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7164\/antibiotics.57.326","article-title":"Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).","volume":"57","author":"Leadbetter","year":"2004","journal-title":"J. Antibiot."},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/jac\/27.1.55","article-title":"Time-dependent killing of Clostridium difficile by metronidazole and vancomycin.","volume":"27","author":"Levett","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1128\/AAC.01830-13","article-title":"In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/jac\/5.5.613","article-title":"Paradoxical effect of aminoglycoside antibiotics on the growth of Gram-negative bacilli.","volume":"5","author":"Lorian","year":"1979","journal-title":"J. Antimicrob. Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.","author":"Louie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1128\/AAC.00124-14","article-title":"Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis and Enterococcus faecium.","volume":"58","author":"Mascio","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.","volume":"63","author":"McKay","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B29","year":"1999","journal-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline"},{"key":"B30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000104471","article-title":"Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.","volume":"53","author":"Odenholt","year":"2007","journal-title":"Chemotherapy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1086\/381972","article-title":"Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.","volume":"38","author":"Pankey","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B32","first-page":"1","year":"2012","journal-title":"BacTiter-GloTM Microbial Cell Viability Assay Technical Bulletin TB337."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1093\/cid\/cis337","article-title":"Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.","author":"Sears","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.","volume":"108","author":"Surawicz","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \u201cStatic vs. Cidal\u201d: a systemic literature review.","volume":"66","author":"Wald-Dickler","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7786","DOI":"10.1128\/AAC.01476-15","article-title":"Eagle effect in nonreplicating persister mycobacteria.","volume":"59","author":"Wu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/0016-5085(85)90206-9","article-title":"Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.","volume":"89","author":"Young","year":"1985","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays.","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.01420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T06:37:33Z","timestamp":1571553453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.01420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":38,"alternative-id":["10.3389\/fmicb.2018.01420"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2018.01420","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,2]]},"article-number":"1420"}}